Expression of cancer stem cell markers and their prognostic significance in stage IIIA non-small cell lung cancer

Table 1 Relationship between non-small cell lung cancer clinical features and overall survival

Characteristic	Univariate analysis			Multivariate analysis
	OS (95%CI)	HR (95%CI)	P value	HR (95%CI)	P value
Gender
Male	614.2 (449.6-715.3)
Female	581.7 (336.4-828.5)	1.122 (0.527-2.418)	0.759
Age (years)
< 65	688.7 (581.6-814.9)
≥ 65	554.3 (274.3-682.1)	1.903 (1.059-3.398)	0.043	1.952 (1.087-2.481)	0.029
Smoking history
Yes	639.3 (477.5-814.9)
No	584.5 (335.6-711.3)	0.981 (0.551-1.763)	0.954
Pathological type
LUSC	625.8 (451.7-763.4)
LUAD	597.2 (434.5-735.3)	0.873 (0.635-1.492)	0.897
Tumor position
Central	680.7 (582.3-774.6)
Peripheral	587.8 (361.5-708.6)	1.395 (0.772-2.521)	0.264
pT stage
T1	708.4 (204.3-1212.6)
T2	556.2 (361.4-715.8)	0.918 (0.395-2.156)	0.847
T3	695.7 (589.3-802.5)	0.931 (0.337-2.578)	0.891
T4	616.1 (450.4-782.6)	1.163 (0.442-3.073)	0.772
pN stage
N0	585.7 (582.6-590.3)
N1	681.5 (365.7-997.4)	0.796 (0.278-2.274)	0.675
N2	559.3 (361.2-715.8)	0.762 (0.285-1.998)	0.581
CEA (ng/mL)
≥ 3.60	647.3 (582.6-715.8)
< 3.60	412.7 (273.9-643.4)	1.712 (1.008-2.572)	0.047	1.256 (0.987-1.976)	0.086
SCC (ng/mL)
≥ 1.10	611.8 (336.7-714.8)
< 1.10	453.6 (359.2-671.5)	1.408 (1.002-1.981)	0.045	1.119 (0.978-1.421)	0.095
NSE (ng/mL)
≥ 21.30	583.6 (551.7-711.8)
< 21.30	662.7 (453.2-709.4)	0.977 (0.935-0.999)	0.049	0.982 (0.951-1.016)	0.102
CA125 (kU/L)
≥ 30.00	662.4 (478.5-724.7)
< 30.00	483.5 (271.6-609.3)	1.018 (1.004-1.052)	0.048	1.072 (0.993-1.217)	0.091
Squamous
Without	558.9 (336.5-708.4)
With	636.2 (581.9-718.5)	0.845 (0.483-1.479)	0.558
Acinar
Without	642.3 (478.6-715.4)
With	559.2 (361.5-714.8)	0.985 (0.561-1.774)	0.996
Lepidic
Without	585.2 (451.6-710.7)
With	647.3 (582.9-715.1)	5.976 (0.753-47.871)	0.093
Micropapillary
Without	647.5 (582.3-715.9)
With	303.2 (270.8-709.5)	2.554 (1.243-5.256)	0.013	2.716 (1.259-5.837)	0.013
Papillary
Without	647.3 (478.5-715.6)
With	556.7 (270.4-709.2)	1.351 (0.732-2.495)	0.343
Solid
Without	638.5 (559.7-714.4)
With	381.6 (270.2-734.8)	1.047 (0.583-1.886)	0.892
Chemotherapy
Yes	617.5 (478.6-710.7)
No	586.3 (314.4-725.9)	0.991 (0.542-1.816)	0.965
PORT
Yes	648.2 (361.7-936.5)
No	589.4 (450.3-709.2)	1.116 (0.403-3.107)	0.837

OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; LUSC: Lung squamous cell carcinoma; LUAD: Lung adenocarcinoma; CEA: Carcinoembryonic antigen; SCC: Squamous cell carcinoma; NSE: Neuron-specific enolase; CA125: Cancer antigen-125; PORT: Postoperative radiotherapy.

Table 2 Cancer stem cells marker immunohistochemistry H-score results

Variables	NSCLC (n = 61)
OCT4
Low H-score	40 (65.57)
High H-score	21 (34.43)
TROP-2
Low H-score	34 (55.74)
High H-score	27 (44.26)
ABCG2
Low H-score	17 (27.87)
High H-score	44 (72.13)
p75NTR
Low H-score	17 (27.87)
High H-score	44 (72.13)

NSCLC: Non-small cell lung cancer; OCT4: Octamer-binding transcription factor 4; TROP-2: Trophoblast cell surface antigen-2; ABCG2: ATP-binding cassette subfamily G member 2; p75NTR: P75 neurotrophin receptor.